Update Novo Nordisk
Novo Nordisk lowered its 2025 outlook due to slower growth in Wegovy and Ozempic, driven by rising competition and concerns about unsafe knockoff drugs. Despite the stock dropping 22%, the company still expects solid profit growth and trades at a historically low valuation, making this a buying opportunity rather than a reason to panic.Stocks